King & Spalding represented GlaxoSmithKline (GSK) on its acquisition of Okairos, a specialist developer of vaccine platform technologies, for €250 million in cash.
Details of the transaction can be found here.
King & Spalding acted for GSK on the deal. Partner Jack Capers (Atlanta) and senior associate Marcus Young (London) co-ordinated a cross-border team on corporate matters. London partner Pulina Whitaker worked on employment law issues. Amstutz Greuter advised on Swiss law matters and Pirola Pennuto Zei & Associati advised on Italian law matters.
“We are extremely pleased to have represented GSK on such a strategically important deal that has huge potential for the development of the company’s vaccine portfolio,” commented Capers. “It is another great instruction that highlights King & Spalding’s excellent pharmaceutical expertise.”
The transaction is the second high-profile M&A matter that King & Spalding has closed for GSK in the past year. In June 2012, the same team represented GSK unit Stiefel on the £196 million acquisition of Toctino.
“These are the types of premium transactions that illustrate the strength and depth of K&S’ transactional team, both in London and internationally,” added Young. “We are proud that key clients such as GSK continue to select us for complex, cross-border instructions.”
